Literature DB >> 8721773

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs.

J Markussen1, S Havelund, P Kurtzhals, A S Andersen, J Halstrøm, E Hasselager, U D Larsen, U Ribel, L Schäffer, K Vad, I Jonassen.   

Abstract

We have synthesized insulins acylated by fatty acids in the epsilon-amino group of LysB29. Soluble preparations can be made in the usual concentration of 600 nmol/ml (100 IU/ml) at neutral pH. The time for 50% disappearance after subcutaneous injection of the corresponding TyrA14(125I)-labelled insulins in pigs correlated with the affinity for binding to albumin (r = 0.97), suggesting that the mechanism of prolonged disappearance is binding to albumin in subcutis. Most protracted was LysB29-tetradecanoyl des-(B30) insulin. The time for 50% disappearance was 14.3 +/- 2.2 h, significantly longer than that of Neutral Protamine Hagedorn (NPH) insulin, 10.5 +/- 4.3 h (p < 0.001), and with less inter-pig variation (p < 0.001). Intravenous bolus injections of LysB29-tetradecanoyl des-(B30) human insulin showed a protracted blood glucose lowering effect compared to that of human insulin. The relative affinity of LysB29-tetradecanoyl des-(B30) insulin to the insulin receptor is 46%. In a 24-h glucose clamp study in pigs the total glucose consumptions for LysB29-tetradecanoyl des-(B30) insulin and NPH were not significantly different (p = 0.88), whereas the times when 50% of the total glucose had been infused were significantly different, 7.9 +/- 1.0 h and 6.2 +/- 1.3 h, respectively (p < 0.04). The glucose disposal curve caused by LysB29-tetradecanoyl des-(B30) insulin was more steady than that caused by NPH, without the pronounced peak at 3 h. Unlike the crystalline insulins, the soluble LysB29-tetradecanoyl des-(B30) insulin does not elicit invasion of macrophages at the site of injection. Thus, LysB29-tetradecanoyl des-(B30) insulin might be suitable for providing basal insulin in the treatment of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721773     DOI: 10.1007/BF00418343

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Atomic structure and chemistry of human serum albumin.

Authors:  X M He; D C Carter
Journal:  Nature       Date:  1992-07-16       Impact factor: 49.962

2.  Albumin immobilized on agarose as a tool for measuring ligand binding of proteins or peptides.

Authors:  R G Reed; T Gates; T Peters
Journal:  Anal Biochem       Date:  1975-12       Impact factor: 3.365

3.  Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM.

Authors:  A Frid; J Ostman; B Linde
Journal:  Diabetes Care       Date:  1990-05       Impact factor: 19.112

4.  Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30.

Authors:  J Markussen; I Diers; P Hougaard; L Langkjaer; K Norris; L Snel; A R Sørensen; E Sørensen; H O Voigt
Journal:  Protein Eng       Date:  1988-07

5.  Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain.

Authors:  J Markussen; P Hougaard; U Ribel; A R Sørensen; E Sørensen
Journal:  Protein Eng       Date:  1987-06

Review 6.  Serum albumin.

Authors:  T Peters
Journal:  Adv Protein Chem       Date:  1985

Review 7.  Fatty acid binding to plasma albumin.

Authors:  A A Spector
Journal:  J Lipid Res       Date:  1975-05       Impact factor: 5.922

8.  Receptor-binding region of insulin.

Authors:  R A Pullen; D G Lindsay; S P Wood; I J Tickle; T L Blundell; A Wollmer; G Krail; D Brandenburg; H Zahn; J Gliemann; S Gammeltoft
Journal:  Nature       Date:  1976-02-05       Impact factor: 49.962

9.  Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies.

Authors:  U Ribel; P Hougaard; K Drejer; A R Sørensen
Journal:  Diabetes       Date:  1990-09       Impact factor: 9.461

10.  NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.

Authors:  S Jørgensen; A Vaag; L Langkjaer; P Hougaard; J Markussen
Journal:  BMJ       Date:  1989-08-12
View more
  36 in total

1.  NB1-C16-insulin: site-specific synthesis, purification, and biological activity.

Authors:  H Mei; C Yu; K K Chan
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

Review 2.  Insulin analogues and management of diabetes mellitus.

Authors:  B Vaidyanathan; P S Menon
Journal:  Indian J Pediatr       Date:  2000-06       Impact factor: 1.967

3.  Simulations of a membrane-anchored peptide: structure, dynamics, and influence on bilayer properties.

Authors:  Morten Ø Jensen; Ole G Mouritsen; Gunther H Peters
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

4.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

5.  Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives.

Authors:  Ib Jonassen; Svend Havelund; Ulla Ribel; Anne Plum; Mette Loftager; Thomas Hoeg-Jensen; Aage Volund; Jan Markussen
Journal:  Pharm Res       Date:  2006-12-21       Impact factor: 4.200

6.  Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

Authors:  Mischa R Müller; Kenneth Saunders; Christopher Grace; Macy Jin; Nicole Piche-Nicholas; John Steven; Ronan O'Dwyer; Leeying Wu; Lam Khetemenee; Yulia Vugmeyster; Timothy P Hickling; Lioudmila Tchistiakova; Stephane Olland; Davinder Gill; Allan Jensen; Caroline J Barelle
Journal:  MAbs       Date:  2012 Nov-Dec       Impact factor: 5.857

Review 7.  Insulin analogues: new therapies for type 2 diabetes mellitus.

Authors:  M Angelyn Bethel; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 8.  Insulin lispro (Humalog), the first marketed insulin analogue: indications, contraindications and need for further study.

Authors:  A L Puttagunta; E L Toth
Journal:  CMAJ       Date:  1998-02-24       Impact factor: 8.262

Review 9.  An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.

Authors:  Katarina Raslova
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

10.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.